Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

IDS’ laser-based breast imaging system requires PMA

You may also be interested in...



Qiagen Launches Colorectal Cancer Companion Diagnostic With PMA Approval

Firm’s therascreen KRAS test will guide Erbitux drug treatment for patients with metastatic colorectal cancer following FDA approval, announced July 6. About 110,000 U.S. patients annually could benefit from the test for the indication, representing a $20 million market opportunity.

New Products In Brief

Berlin Heart’s Excor Pediatric ventricular assist device gains FDA humanitarian device exemption approval. Cerevast Therapeutics gains CE mark for Clotbust ER ultrasound device to treat ischemic strokes. More new products.

OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End

OraSure Technologies expects to complete a PMA filing for its OraQuick Advance rapid HIV-1 and -2 over-the-counter saliva test by the end of the year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel